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ABSTRACT 
Amylin acts acutely via the area postrema to reduce food intake and body weight but also 
interacts with leptin over longer periods of time, possibly via the ventromedial hypothalamus 
(VMH), to increase leptin signaling and phosphorylation of STAT3 (pSTAT3). We postulated 
that amylin enhances VMH leptin signaling by inducing IL-6 which then interacts with its gp130 
receptor to activate STAT3 signaling and gene transcription downstream of the leptin receptor. 
We found that components of the amylin receptor (RAMPs1-3, CTR1a,b) are expressed in 
cultured VMH astrocytes, neurons and microglia, as well as in micropunches of arcuate and 
ventromedial hypothalamic (VMN) nuclei. Amylin exposure for 5 d increased IL-6 mRNA 
expression in VMH explants and microglia by 2-3 fold as well as protein abundance in culture 
supernatants by 5- and 2-fold. Amylin had no similar effects in cultured astrocytes or neurons. In 
rats, 5 d amylin treatment decreased body weight gain and/or food intake and increased 
ventromedial nucleus (VMN) IL-6 mRNA. Similar 5 d amylin treatment increased VMN leptin-
induced pSTAT3 expression in wild type mice and rats infused with lateral ventricular IgG but 
not in IL-6 knockout mice or rats infused with ventricular IL-6 antibody. Lateral ventricular 
infusion of IL-6 antibody also prevented the amylin-induced decrease of body weight gain. 
These results show that amylin-induced VMH microglial IL-6 production is the likely 
mechanism by which amylin treatment interacts with VMH leptin signaling to increase its effect 
on weight loss. 
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INTRODUCTION 
 
Amylin is synthesized by pancreatic β-cells and is co-released with insulin in response to food 
intake and increasing glucose levels (1). However, while insulin stimulates nutrient disposal and 
storage, amylin limits nutrient availability by inhibiting food intake, gastric emptying and 
digestive secretions (2; 3). The amylin receptor is composed of a calcitonin receptor (CTR) 
heterodimerized with a receptor activity modifying protein (RAMP) (4; 5). There are two splice 
variants of CTR, 1a and 1b (4; 6) and three known RAMP subtypes (RAMP1, 2, 3) providing six 
possible combinations for expression of the amylin receptor (7). The CTR can be activated by 
peptides such as calcitonin and amylin (8). However, CTR has an enhanced affinity for amylin 
when combined with RAMPs (9). Amylin binds to its receptors which are distributed throughout 
the brain. These include the area postrema (AP), nucleus of the solitary tract (NTS), the lateral 
hypothalamic area, ventromedial (VMN) and arcuate (ARC) hypothalamic nuclei and the ventral 
tegmental area (VTA) (10-14). 
 
Several studies have documented the satiating effect of amylin via its action on the AP (3; 15-
17). The VTA has also been demonstrated as a site of amylin’s action (18).  However, amylin 
has also been suggested to act in the VMN and ARC to enhance leptin signaling and 
synergistically decrease food intake and body weight when co-administered with leptin in obese 
rats and humans, as well as lean rats (19-22). Systemic amylin administration increases 
expression of the intracellular signaling form of the leptin receptor, Lepr-b, as well as binding of 
leptin to its receptors in the ARC and VMN. This is associated with an increase in VMN leptin-
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induced phosphorylation of signal transducer and activator of transcription-3 (pSTAT3) (19; 20), 
one of the major signaling pathways downstream of the leptin receptor (23; 24).   
 
Since there is currently no evidence that amylin acting at the AP should increase VMN leptin 
signaling, we postulated that amylin might act independently in the ventromedial hypothalamus 
(VMH: ARC + VMN) to stimulate the production of IL-6 which then acts on its receptor 
signaling complex, IL6 receptor (IL6R) coupled to gp130, to activate STAT3 as a means of 
increasing downstream leptin signaling. This hypothesis is based on the finding that endogenous 
IL-6 increases leptin sensitivity (25) and that increased VMH IL-6 production increases leptin 
signaling and anorectic sensitivity in swim-stressed rats, an effect that is blocked by 
intraventricular administration of IL-6 antibodies (26).  Using in vivo and in vitro methods, we 
found that amylin causes VMH microglia to produce IL-6 and increases IL-6 mRNA expression 
in VMN micropunches from rats treated with amylin. Amylin treatment increased VMN leptin-
induced pSTAT3 expression in wild type (wt) mice and rats, but failed to do so in IL-6 knockout 
(ko) mice or rats infused in their lateral ventricles (LV) with IL-6 antibody. These results 
strongly suggest that amylin enhances VMH leptin signaling by directly stimulating microglia 
IL-6 production which then acts on VMH neurons to increase their leptin-induced STAT3 
phosphorylation.  
 
RESEARCH DESIGN AND METHODS 
 
Animals 
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Outbred male Sprague-Dawley rats were purchased from Charles River Laboratories; 
Wilmington, MA). IL-6 knockout (IL-6 ko; B6;129S6-Il6
tm1Kopf
/J) and wild-type (wt; C57BL/6J) 
mice were purchased from Jackson Laboratories (Bar Harbor, ME). Rats were housed at 23-24 
°C on a reverse 12:12-h light-dark cycle (lights off at 0800) with ad libitum access to chow (3.36 
kcal/g, 13.5% fat; Purina #5001) and water. Mice were fed mouse chow (3.81 kcal/g, 25% fat; 
Purina #5015) and housed on a conventional 12:12 light-dark schedule with lights off at 0900. 
All work was in compliance with the Institutional Animal Care and Use Committee of the E. 
Orange Veterans Affairs Medical Center. 
 
In Vitro Amylin Effects 
VMH Explants: Postnatal day 21-28 (P21-28) Sprague-Dawley male rats were sacrificed and 
350 µm VMH sections (from bregma -2.30 mm to -3.60 mm (27)) were cut with a vibratome in 
oxygenated slushed aCSF (containing in mmol/L: 118 NaCl, 3 KCl, 1 MgCl2, 2.5 NaHCO3, 1.5 
CaCl
2
, 1.2 NaH2PO4, 5 Hepes, 2.5 glucose, 15 sucrose, pH 7.4). Explant slices were transferred 
to individual wells and maintained in Neurobasal (Invitrogen Grand Island, NY) containing 10% 
fetal bovine serum (FBS), 5 mmol/L glucose, 10 µg/mL gentamycin, 10000 U/ml 
Penicillin/Streptomycin at 37 °C for 5 d. They were exposed twice daily to 10 µmol/L amylin 
(Bachem, Torrance, CA) or PBS control (n=9/group). On day 5, media were collected and stored 
at -80 °C for cytokine assays.  Slices were placed in RNA Later (Ambion, Grand Island, NY), 
the VMH was punched under microscopic guidance and mRNA expression was assayed by 
quantitative rt-PCR (QPCR; Applied Biosystems, Grand Island, NY) (28; 29). 
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Primary VMN neuronal cultures: P21-28 rats were perfused with a 4% sucrose solution and 
neurons were dissociated from VMN punches as previously described (28; 29). Neurons were 
cultured in growth media (Neurobasal plus 2.5 mmol/L glucose) for 5 d and exposed twice daily 
to 10 µmol/L amylin (Bachem, Torrance, CA) or PBS (n=9/group). On day 5, media were 
collected and kept at -80 °C for cytokine assays. Neurons were exposed to 120 µL of lysis buffer 
(Ambion, Grand Island, NY) from which mRNA was extracted and gene expression assayed by 
QPCR (Applied Biosystems, Grand Island, NY) (28). 
 
Primary VMH astrocyte cultures: The VMH was dissected from P21-P28 rats and triturated in 
Neurobasal-A (Invitrogen, Grand Island, NY) containing 2.5 mmol/L glucose, 0.23 mmol/L 
sodium pyruvate, 10000 U/mL penicillin/streptomycin, 10 µg/mL gentamycin, 10% FBS at pH 
7.4 and astrocytes were dissociated as previously described (30). The day prior to amylin 
treatment, astrocytes were washed with PBS and serum free Neurobasal-A was added overnight. 
Astrocytes were then exposed to vehicle alone (PBS) or 10 µmol/L amylin twice daily for 5 d 
(n=9/group). Terminally, media were collected and stored at -80 °C for cytokine assay. 
Astrocytes were exposed to 120 µL of lysis buffer (Ambion, Grand Island, NY) followed by 
mRNA extraction, reverse transcription and quantification by QPCR (Applied Biosystems, 
Grand Island, NY) (28). 
 
Primary cortical and hypothalamic microglia cultures: Primary mixed glial cortical and 
hypothalamic cultures were generated from cortical or hypothalamic tissue from P2 rats. Intact 
brains were removed and dissected free of meninges. Tissue samples were placed in 2% 
glucose/PBS and digested in 0.25% trypsin for 20 min. Complete Minimum Essential Media 
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(MEM-C, Invitrogen, Grand Island, NY) containing 10% FBS, glutamine, 10000 U/mL 
penicillin/streptomycin and  6% glucose were then added. The tissue was gently triturated with a 
10 mL pipet and passed through a 130 µm screen. Cells were pelleted at 1200 rpm for 5 min and 
the pellet was suspended in 10 ml MEM-C and passed through a 35 µm screen. Cells were 
counted and plated at a density of 1.5 x 10
6
 cells/ml. Cells were cultured in 75 cm
2
 tissue culture 
flasks and maintained at 37°C in 5% CO2. When cultures reached confluency, microglia cells 
were harvested by shaking at 250 rpm for 90 min, and then pelleted at 1200 rpm for 5 min, 
suspended in Dulbecco's Modified Eagle's Medium and Ham's F-12 Nutrient Mixture 
(DMEM/F12, Invitrogen, Grand Island, NY) containing 10% FBS and plated at a density of 4 x 
10
5
 cells/ml. At 90% confluency, microglia were treated with vehicle (PBS) or 1 µmol/L amylin 
twice daily for 5d (n=6/group). Terminally, media were collected and stored at -80°C for 
cytokine assay. Microglia were treated with 120 µl of lysis buffer (Ambion, Grand Island, NY), 
mRNA was extracted and assayed by QPCR. 
 
Tissue Culture Cytokine Measurement: Interleukin-1beta (IL-1β), interleukin-6 (IL-6), 
interleukin-10 (IL-10), and tumor necrosis factor alpha (TNF-α) were measured in culture 
supernatants using a customized V-Plex proinflammatory assay for rat (K15044D; Meso Scale 
Discovery [MSD], Gaithersburg, MD). For all assays, culture supernatants were diluted 1 to 2 in 
the diluent provided. Samples collected from VMH explants and neuronal cultures were 
incubated in the coated MSD plate for 2 h at room temperature, while samples from astrocyte 
and microglia cultures were incubated overnight at 4 °C, to increase sensitivity of the assay. 
Assays were otherwise completed per the manufacturer’s instructions.  Detection limits of the 
assay were 6.92 pg/mL for IL-1β, 13.8 pg/mL for IL-6, 16.4 pg/mL for IL-10, and 0.72 pg/mL 
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for TNF-α. Plates were read using the MESO QuickPlex SQ 120 (MSD) and analyzed using 
MSD Discovery Workbench analyzer and software package. Cytokine levels were corrected 
against cyclophilin mRNA to normalize sample size. 
 
In vivo Amylin Effects 
After 1 wk of acclimation, 9-10 wk old (300-350 g) rats were randomized by body weight into 
experimental groups, anesthetized and implanted with subcutaneous, intrascapular minipumps 
(Alzet Model 2001; Durect Corp., Cupertino, CA) (20) 
 
Experiment 1 (Tables 3, 4, Figure 2): rats were divided into 3 groups: Amylin (dissolved in 
0.9% saline infused at 100 µg/kg/d; Bachem, Torrance, CA) treated and fed ad libitum), Pair-fed 
(0.9% saline infusion with intake matched to previous day’s intake by Amylin rats) and Ad-lib 
fed (0.9% saline infusion). Body weight and food intake were monitored every 2 d.  Terminally, 
food was removed at lights on (2000) the evening before and rats were rapidly decapitated at 
lights off the next morning. Brains were removed, snap frozen on dry ice and stored at -80 °C for 
mRNA analysis by quantitative real-time PCR (QPCR) (31). Resulting target gene expression 
was expressed as a ratio of the constitutively expressed gene, cyclophilin.  
 
Experiment 2 (Figure 3): 9-10 wk old male rats were implanted in the LV (X= 1.6 mm, Y= 0.9 
mm, Z= 4 mm -relative to dura) with a cannulae linked to a subcutaneously-implanted osmotic 
minipump (Azlet Model 2002 and Brain Infusion Kit 2) to infuse either IL-6 antibody (400 
ng/kg/day; Santa Cruz sc-7920) or IgG control (400 ng/kg/d Santa Cruz sc-2027). After 5 d 
recovery, rats were implanted subcutaneously with a second osmotic minipump (Alzet 2001) for 
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saline (0.9%) or amylin (100 µg/kg/d) for an additional 5 d.  Body weight and food intake were 
monitored daily. Terminally, food was removed 2 h before lights off (0700). Rats were injected 
with murine leptin (5 mg/kg, i.p. in PBS; NHPP, Torrance, CA) at lights off, anesthetized 
(ketamine/xylazine) 45 min later and rapidly perfused with 0.9% saline followed by 4% 
paraformaldehyde (PFA) in PBS. Brains were removed, post-fixed overnight in 4% PFA and 
transferred the next day to KPBS containing 20% sucrose for 24h. The brains were then frozen in 
2-methylbutane.  
 
Amylin Effects on IL-6 Knockout (IL-6 ko) Mice 
9 wk old IL-6 ko and wild type (wt) mice were fed mouse chow ad libitum throughout the 
experiment. After 1 wk of acclimation, mice were randomized by body weight into four groups, 
anesthetized and implanted with subcutaneous, intrascapular minipumps (Alzet Model 1002; 
Durect Corp., Cupertino, CA). Pumps contained amylin (Bachem, Torrance, CA) in 0.9% saline 
(wt-A and IL-6 ko-A infused at 1 mg/kg/d) or 0.9% saline vehicle (wt-S and IL-6 ko-S). Body 
weight and food intake were monitored bi-weekly for 2 wk. Terminally, food was removed at 2 h 
before lights off. Mice were injected with murine leptin (5 mg/kg, i.p. in PBS; NHPP, Torrance, 
CA) at lights off, anesthetized (ketamine/xylazine) 45 min later and rapidly perfused with 0.9% 
saline followed by 2% PFA in PBS (32). Brains were removed, post-fixed overnight in KPBS 
containing 20% sucrose and frozen with 2-methylbutane.  
 
125
I Amylin Receptor Binding Autoradiography: Brains from non-fasted rats were removed, 
frozen on powdered dry ice and 12 µm sections were cut through the midpoint of the ARC, 
VMN and dorsomedial nucleus (DMN) pars compacta (27), mounted on gel-coated slides, 
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desiccated and stored at -80 °C. Amylin receptor binding was carried out by methods adapted 
from Sexton et al. (33). Briefly, sections were thawed and rinsed in incubation buffer (20 
mmol/L HEPES containing 100 mmol/L NaCl, 1 mg/mL BSA and 0.5 mg/mL Bacitracin). 
Sections were then incubated at room temperature for 1 h in incubation buffer containing 70-75 
pmol/L 
125
I amylin (NEX44; Perkin Elmer, Boston, MA) plus 1 µmol/L unlabeled rat amylin 
(non-specific “binding”; Bachem, Torrance, CA). Slides were rinsed in incubation buffer at 4 °C 
and rinsed two more times at 4 °C in modified incubation buffer (20 mmol/L HEPES containing 
100 mmol/L NaCl). After a brief dip in dH2O, sections were dried under forced cold air and 
desiccated for 24 h. Sections were then exposed to BioMax MR Film (Kodak, Rochester, NY) at 
-80 °C for 7-14 d.  
 
pSTAT3 Immunohistochemistry: Brain sections (30 µm) were cut through the mid-VMH (27) 
from saline and amylin-treated wt and IL-6ko mice and mounted on Superfrost Plus slides. Free-
floating (30 µm) sections were cut from brains of control and amylin-treated rats infused in the 
LV with IgG or IL-6 antibody.  Slides and free-float sections were stored in antifreeze at -20 °C 
until processed for leptin-induced pSTAT3 immunohistochemistry using rabbit anti-pSTAT3 
antibody (1:1000; Cell Signaling Tech., Danvers, MA) using methods previously described (31). 
Three consecutive sections were counted per brain using a Bioquant image analysis system 
(Bioquant, Nashville, TN) by an experimentally naive observer.  
 
Statistics: Statistical comparisons among variables for in vivo studies were made by 1-way 
ANOVA with Bonferroni post-hoc analysis. Body weight gain and food intake were analyzed by 
1-way ANOVA with repeated measures. Food efficiency was calculated by dividing the body 
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weight gain in grams by the total food intake in kcal and multiplying the total by 1000. All data 
are expressed as mean ± SEM. Statistical analysis was performed using SYSTAT software 
(SYSTAT, Chicago, IL).  Comparisons between control and amylin-treated groups in in vitro 
studies were assessed using t-test for nonparametric statistics (GraphPad Prism, La Jolla, CA).  
 
RESULTS 
 
Distribution of 
125
I Amylin Binding  
We confirmed previous findings (33; 34) that 
125
I amylin binds to the ventromedial portion of the 
VMN, as well as the ARC, dorsomedial nucleus, perifornical and medial tuberal hypothalamus 
and the medial amygdalar nucleus (Fig. 1). There was little binding in cerebral cortex or 
hippocampal structures at the rostro-caudal level through the midpoint of the VMH. Hindbrain 
structures were not examined since the emphasis here was on the effects of amylin on forebrain 
structures. No amylin binding was found in sections co-incubated with unlabeled amylin (See 
supplemental Figure 1).  
 
In Vitro effects of Amylin on Hypothalamic Explants, Neurons, Astrocytes and Microglia. 
Exposing VMH explants to 10 µmol/L amylin for 5 d increased IL-6 mRNA expression by 320% 
(Table 1) and secretion of IL-6 protein 5.5-fold (Table 2). Amylin also increased mRNA 
expression of RAMP1 and 2 subunits of the amylin receptor by 122% and 103%, respectively, 
while it decreased expression of the CTR1b subunit of the amylin receptor by 72% (Table 1).  In 
addition, amylin increased IL-10 secretion 7-fold (Table 2). 
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To assess the specific cellular source of IL-6 production within the VMH, primary cultures of 
VMH neurons, microglia and astrocytes, as well as cerebral cortical microglia were incubated 
with amylin (1-10 µmol/L) for 5 d. Exposure of primary hypothalamic microglial cultures from 
P2 rats to 1 µmol/L amylin increased IL-6 mRNA expression by 211% (Table 1) and IL-6 
protein production by 204% (Table 2). Amylin also increased microglial CTR1b mRNA 
expression by 56%, and decreased both leukemia inhibitory factor (LIF), a member of the IL-6-
type class cytokine family that acts though gp130, and gp130 mRNA expression by 29% (Table 
1). The amylin-induced increase in IL-6 mRNA expression was not specific to hypothalamic 
microglia since amylin also increased cerebral cortex microglial IL-6 mRNA expression by 
140% (Table 1) and IL-6 media secretion by 310% (Table 2). Amylin also increased the 
secretion of TNF-α by cortical microglia by 158% (Table 2). Amylin exposure had no effect on 
neuronal cytokine mRNA or protein production (Tables 1 and 2), although it did increase 
neuronal SOCS3 (an inhibitor of JAK/STAT3 signaling) mRNA expression by 33% (Table 1). 
Similarly, while amylin had no effect on cultured astrocyte IL-6 mRNA expression, it did 
increase TNF-α mRNA by 113%, IL-1β by 211% and ciliary neurotrophic factor (CNTF) by 
74%, while decreasing LIF expression by 61% (Table 1).  
 
In Vivo Effects of Amylin on VMH Cytokine Production (Experiment 1) 
Male, 9-10 wk old rats were infused subcutaneously with either amylin or vehicle for 5 d. Rats 
pair-fed to amylin-treated rats served as additional controls. Amylin-treated rats consumed 24% 
fewer kcals overall (p=0.001, Table 3; Fig. 2B) and gained 86% less body weight compared to ad 
libitum-fed controls over 5 d of treatment (Table 3; Fig. 2A). This resulted in an 82% lower feed-
efficiency overall in amylin-treated rats suggesting an amylin-induced increase in energy 
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expenditure (Table 3).  In VMN micropunches from these rats, expression of IL-6 mRNA was 
increased by 46% in amylin-treated rats vs. ad libitum controls, while pair-feeding had no effect 
on IL-6 expression (Table 4). Associated with the increase in VMN IL-6 expression, VMN Lepr-
b mRNA expression was increased by 60% (Table 4) compared to pair-fed controls. Also, 
expression of VMN CTR1a and b were increased by 120% and 176%, respectively, compared to 
pair-fed rats (Table 4). The amylin-induced changes appeared to be specific to IL-6 as amylin 
had no effects on the mRNA expression of any other VMN or ARC cytokine.  Despite the lack 
of significant amylin-induced changes in IL-6 or Lepr-b expression in the ARC, amylin-treated 
rats had significant increases in both NPY and AgRP mRNA expression compared to ad libitum 
or pair-fed controls (Table 4).  
 
Amylin Effects on Rat VMH Leptin Signaling of LV IL-6 Antibody Infusions (Experiment 
2) 
To confirm the hypothesis that the amylin sensitizing effect on leptin signaling is due to an 
amylin-induced increase in IL-6 activation of JAK/STAT3 signaling, IgG or IL-6 antibodies 
were infused into the LV of rats for 5 d. At that time, rats were then additionally infused 
subcutaneously with either amylin or vehicle for 5 d more. Neither IgG nor IL-6 antibodies 
altered food intake or body weight gain over the first 5 d of LV infusions (Fig. 3A, B). After an 
additional 5 d of amylin treatment, LV IgG-infused rats decreased their body weight gain and 
food intake by 96% and 27%, respectively, as compared to IgG-Saline rats (Fig. 3C, D). On the 
other hand, LV IL-6 antibody infusion attenuated the amylin-induced decrease in body weight 
gain by 37% (Fig. 3C) but had no effect on amylin-induced reduction in food intake (Fig. 3D). 
Most importantly, 10 d of IL-6 antibody treatment and 5 d of amylin infusion prevented the 
Page 14 of 38Diabetes
amylin-induced enhancement of leptin-induced VMN pSTAT3 expression seen in IgG Amylin 
rats by 25% (Fig.3E). However, IL-6 antibody infusion had no effect on amylin’s enhancement 
of leptin-induced pSTAT3 expression in the ARC (Fig.3E). These data strongly suggest that IL-6 
is required for the amylin sensitizing effects on VMH leptin signaling through which it 
contributes to amylin-induced reductions in body weight gain but not food intake.  
 
Effects of Amylin on Leptin Signaling in IL-6 ko Mice 
To further confirm the hypothesis that the amylin sensitizing effect on leptin signaling is due to 
an amylin-induced increase in IL-6 activation of JAK/STAT3 signaling, wt and IL-6 ko mice 
were infused with either amylin or vehicle by minipumps for 2 wk. Although there were no 
significant differences in body weight gain or food intake among the groups, there was a trend 
towards decreased body weight gain in amylin-treated wt controls (Fig. 4A, B See supplemental 
Figure 2). Most importantly, 2 wk amylin treatment was associated with a 67% increase in 
leptin-induced pSTAT3 expression selectively in the VMN of wt but not IL-6 ko mice (Fig. 4C, 
D A, B). These data strongly suggest that IL-6 is required for the amylin sensitizing effects of 
VMH leptin signaling.  
 
DISCUSSION 
 
The goal of this study was to identify the mechanism by which systemic amylin administration 
increases VMH leptin signaling to produce a synergistic effect on weight loss in obese 
individuals (19; 20). We first confirmed that 
125
I amylin binds in the VMH (as well as other 
forebrain areas) and demonstrated, for the first time, that CTR1a and b along with RAMP1-3 
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components of the amylin receptor complex are variably expressed in VMH microglia, 
astrocytes and neurons. We postulated that amylin interacts with leptin signaling by causing cells 
within the VMH to produce IL-6 which is known to phosphorylate STAT3, a common 
downstream mediator of leptin signaling (35; 36), via its IL6R complex. We found that amylin 
did, indeed, increase IL-6 production in both VMH explants and VMN micropunches from rats 
treated in vivo with amylin and that this occurred selectively in microglia but not astrocytes or 
neurons. As previously demonstrated (19; 20), amylin reduced body weight gain and food intake 
in adult rats; this reduced body weight gain was partially reversed by LV infusions of IL-6 
antibody. While high doses of amylin failed to reduce body weight gain or food intake in wt or 
IL-6 ko mice, amylin’s enhancement of VMN leptin-induced pSTAT3 expression was 
completely inhibited in IL-6 ko mice and rats with LV IL-6 antibody infusions. The failure of 
LV IL-6 antibody infusions in rats to completely prevent amylin-induced reductions in body 
weight gain or food intake was not unexpected since amylin is known to produce weight loss and 
anorexia via its actions in the AP (37; 38), as well as in the VTA (18). The failure of LV IL-6 
antibody to reverse the amylin-induced reduction in food intake suggests that the primary role of 
amylin-induced enhancement of VMH leptin signaling via microglial IL-6 production is in 
affecting energy expenditure. This also suggests that amylin’s effects on reducing food intake are 
not mediated via its actions on VMH leptin signaling, but rather via its actions on other brain 
sites; however, it is also possible that the dose of IL-6 antibody used was not sufficient to prevent 
the effect of amylin on food intake. Therefore, because the partial blockade of amylin-induced 
body weight reduction by LV IL-6 antibody infusion was not paired with a decrease in food 
intake, this suggests that amylin’s enhancement of leptin signaling in the VMH likely resulted in 
increased energy expenditure.  
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Our data strongly support the hypothesis that amylin’s enhancement of VMH leptin signaling 
(20) is due to its direct action on VMH microglia to produce IL-6 which then acts on its 
IL6R/gp130 receptor complex (39) to activate STAT3 phosphorylation which is also 
downstream of Lepr-b signaling (40). Activation of STAT3 results in its dimerization and 
translocation into the nucleus where it then alters gene transcription (24). Given the fact that 
systemic amylin treatment increases VMH Lepr-b gene expression, binding of leptin to its cell 
surface receptor in both the ARC and VMN and leptin-induced pSTAT3 expression in the VMN 
(19; 20), our data support the hypothesis that convergence of amylin-induced microglial 
production of IL-6 on STAT3 activation is an important route by which amylin enhances leptin 
signaling in the VMH. Here we confirmed the previous finding that systemic amylin treatment 
increases leptin-induced pSTAT3 expression in the VMN of wt mice (20) and show, for the first 
time, that amylin had no effect on VMN pSTAT3 expression in IL-6 ko mice. Amylin’s 
enhancement of VMN leptin-induced pSTAT3 expression was also inhibited by LV IL-6 
antibody infusion in rats. Such a direct action in the VMH requires that amylin cross the blood-
brain barrier which has been shown to occur (41; 42). However, since amylin exposure did not 
increase Lepr-b expression in isolated VMH explants as it does when given in vivo (20), there 
may be an additional component of amylin’s effect on leptin signaling that is required to alter 
Lepr-b expression in the intact animal. 
 
Interestingly, amylin exposure had differential effects on CTR1 and RAMP expression. For 
example, amylin exposure increased RAMP1 and 2 in VMH explants and RAMP2 and 3 in 
cortical, but not VMH microglial cultures. However, systemic amylin administration in vivo had 
no consistent effect on ARC or VMN RAMP expression. Similarly, CTR1b expression was 
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differentially altered depending upon the tissue examined and type of exposure.  These results 
suggest that there are clear differences between the responses of cortical and VMH microglia to 
amylin, just as cortical and hypothalamic astrocytes differ in their characteristics (43). Given the 
fact that amylin affected CTR and RAMP expression only in cultured microglia but not 
astrocytes or neurons, these results demonstrate feedback by amylin on its own receptor 
selectively in microglia. Similarly, while amylin stimulated VMH microglial IL-6 expression, it 
also had a negative feedback effect (44) on the expression of the gp130 component of the IL-6 
receptor complex (45). In fact, the gp130 family of receptors can be activated by other cytokines 
such as LIF (39; 46), although in our case, amylin altered LIF expression only in cultured 
hypothalamic astrocytes and this was an inhibitory rather than a stimulatory effect.  
 
Although numerous studies (2; 19; 20; 47-49), including ours here in rats, have clearly shown 
that amylin acts alone to decrease food intake and body weight in obese and lean rats and obese 
humans,  it had no such effects in wt mice treated for 2 wk with amylin doses that were 10 times 
higher than those used in rats, despite showing a clear enhancement of wt leptin signaling in the 
VMN. There is no ready explanation for this lack of effect on body weight or food intake in 
amylin-treated wt mice. It is possible that amylin treatment reduced their adiposity but this could 
not be assessed due to methodological requirements for later immunohistochemistry. Also, 
although 5 d of pair-feeding to amylin-treated rats had no effect on ARC NPY or AgRP 
expression, amylin treatment actually increased the expression of these orexigenic peptides. 
Since all of the changes in amylin-induced IL-6 production and leptin signaling occurred 
selectively in the VMN, to the exclusion of ARC Lepr-b-expressing neurons, it is possible that 
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the upregulation of these peptides was indirectly mediated by alterations in VMN leptin 
signaling.   
 
In conclusion, we have demonstrated that, in addition to amylin’s well-known direct effect on 
AP and VTA neurons which mediates much of its anorectic effects (3; 15-18), amylin also acts 
directly to stimulate VMH microglia production of IL-6. This IL-6 is released into the interstitial 
space where it acts on its IL-6/gp130 receptor on Lepr-b-expressing neurons in the VMN to 
enhance leptin’s activation of STAT3 phosphorylation. While amylin acts directly in the AP  to 
decrease food intake and body weight, especially acutely (15; 47; 50), its interaction with leptin 
on weight loss in obese rats and humans appears to depend on its ability to stimulate VMN 
microglial IL-6 production to increase leptin signaling (2; 19; 47; 48). This novel discovery 
provides a potential avenue for discovery of new leptin sensitizers in the treatment of obesity.    
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Table 1: Amylin-induced changes in VMH explant, neuron, astrocyte, hypothalamic and cerebral cortex microglia gene expression 
 Explant Neurons Astrocytes Hypothalamic 
Microglia 
Cortical  
Microglia 
 Control Amylin Control Amylin Control Amylin Control Amylin Control Amylin 
           
IL 6 0.77±0.35 3.24±0.87* 1.39±0.21 1.89±0.17 1.01±0.11 0.78±0.07 0.53±0.07 1.65±0.39* 0.68±0.10 1.63±0.25* 
Il 1-β 1.30±0.29 1.71±0.20 1.17±0.20 1.23±0.19 0.47±0.05 1.46±0.16* 0.76±0.09 1.32±0.22 0.94±0.14 1.21±0.12 
IL-10 Und. Und. Und. Und. Und. Und. 0.89±0.13 0.97±0.19 0.57±0.11 1.11±0.14* 
TNF-α 1.20±0.30 1.86±0.40 1.24±0.20 1.40±0.21 0.67±0.12 1.43±0.17* 2.16±0.28 1.66±0.31 1.07±0.10 0.95±0.12 
LIF 0.78±0.28 0.41±0.15 1.01±0.11 1.08±0.11 1.40±0.10 0.55±0.06* 1.07±0.07 0.76±0.07* 0.90±0.06 1.08±0.08 
CNTF 0.88±0.19 0.69±0.16 1.34±0.26 1.50±0.34 0.74±0.08 1.29±0.16* 1.16±0.08 0.93±0.05 0.95±0.07 0.95±0.12 
gp130 0.17±0.04 0.21±0.10 1.44±0.27 1.20±0.18 1.02±0.05 0.95±0.02 1.21±0.13 0.86±0.07* 1.00±0.07 1.16±0.20 
CTR1a 2.41±0.54 3.80±1.35 1.26±0.05 1.30±0.03 0.71±0.17 0.65±0.1 0.87±0.12 1.13±0.18 0.78±0.12 1.35±0.21 
CTR1b 5.92±0.53 1.65±0.63* 1.03±0.04 1.01±0.06 Und. Und. 0.75±0.11 1.17±0.10* Und Und 
RAMP1 1.23±0.32 2.74±0.49* 0.94±0.05 0.96±0.09 0.78±0.06 1.03±0.12 1.14±0.10 0.87±0.12 1.07±0.09 0.92±0.08 
RAMP2 0.29±0.04 0.59±0.10* 1.03±0.06 1.01±0.07 0.93±0.08 0.97±0.1 1.07±0.09 1.02±0.05 0.95±0.04 1.10±0.04* 
RAMP3 0.89±0.27 1.15±0.15 1.00±0.04 0.96±0.04 0.99±0.07 1.13±0.06 0.74±0.15 1.07±0.13 0.80±0.05 1.24±0.05* 
Lepr-b 1.89±0.60 1.73±0.70 0.75±0.06 0.55±0.06       
SOCS3 0.59±0.20 0.47±0.15 0.98±0.07 1.30±0.12*       
VMH explants, neurons, astrocytes and microglia were incubated with amylin (1-10µmol/L) vs. vehicle (PBS) for 5 days: Data are mean ± SEM of 
duplicate determinations expressed relative to the amount of the mRNA expression of cyclophilin (n=9/group). *P<0.05 or less control vs. amylin in 
each type of cell culture. Und=Undetectable.
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Table 2: Cytokine production after 5d treatment of amylin (1-10µmol/L) in VMH explant, VMH neurons, VMH astrocytes and cortex and 
hypothalamic microglia from male SD rats.  
 Explant Neurons Astrocytes 
Hypothalamic 
microglia 
Cortical  
microglia 
 Control Amylin Control Amylin Control Amylin Control Amylin Control Amylin 
IL-6 368±83 2058±241* 64.4±6.6 82.1±7.2 15.1±1.82 11.3±1.50 28.6±6.59 86.9±21.6* 18.6±3.92 76.5±10.21* 
IL-10 2.46±0.95 18.1±4.62* 2.21±0.41 3.02±0.61 3.75±0.72 3.95±0.57     
IL-1β   7.22±1.17 8.27±2.40 11.9±0.75 10.8±1.52 9.19±2.23 12.54±2.81 11.24±3.54 15.3±1.80 
TNFα 5.27±1.51 12.4±3.32 8.83±0.56 9.88±0.96 0.47±0.05 0.56±0.05 2.44±0.56 3.15±0.72 1.48±0.44 3.82±0.55* 
Cytokine levels in the supernatant of cultures in pg/mL were normalized to the amount of cyclophilin mRNA expression in each tissue, respectively. 
N=9-6/group *P<0.05 or less by t-test vehicle vs. amylin. 
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Table 3: Effects of 5d of systemic amylin (100µg/kg/d) vs. vehicle (0.9% saline) infusions in rats  
 
 Ad-Lib Fed Amylin Pair-Fed 
Body Weight Initial, g 346 ± 2.9 346 ± 2.6 346 ± 3.8 
Final Body Weight, g 369 ± 3.6
a
 349 ± 3.2
b
 356 ± 3.2
b
 
5d Body Weight Gain, g  22 ± 3.8
a
 3.1 ± 2.5
b
 9.6 ± 1.9
ab
 
5d Food Intake, kcal  384 ± 8.6
a
 290 ± 8.3
b
 290 ± 7.5
b
 
5d Feed Efficiency ((body weight 
gain(g)/ food intake (kcal))*1000)  
51± 10
a
 9 ± 9
b
 32 ± 6
ab
 
Values are mean ± SEM. N=9-10/group. Parameters with differing superscripts differ from each other by 
P<0.05 or less.  
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Table 4: ARC and VMN gene expression after 5d of systemic amylin (100µg/kg/d) vs. vehicle (0.9% saline) infusion in rats 
ARC VMN 
 Ad-Lib Fed Amylin Pair-Fed Ad-Lib Fed Amylin Pair-Fed 
IL-6 1.29 ± 0.20
 
1.44 ± 0.08 1.25 ± 0.17 1.66 ± 0.21
a 
2.43 ± 0.15
b
 1.81 ± 0.21
ab
 
IL-1β 0.81 ± 0.18 0.74 ± 0.12 0.80 ± 0.15 1.54 ± 0.27 1.06 ± 0.17 1.27 ± 0.24 
TNFα 1.96 ± 0.18 1.60 ± 0.21 1.64 ± 0.16 1.28 ± 0.18 1.10 ± 0.14 1.15 ± 0.11 
LIF 1.24 ± 0.13 1.05 ± 0.11 1.21 ± 0.08 0.91 ± 0.05 0.89 ± 0.03 1.04 ± 0.06 
CNTF 1.56 ± 0.13 1.52 ± 0.10 1.82 ± 0.13 1.16 ± 0.07 1.25 ± 0.04 1.15 ± 0.05 
gp130 2.53 ± 0.21 2.35 ± 0.15 2.36 ± 0.15 1.40 ± 0.07 1.49 ± 0.06 1.27 ± 0.06 
Lepr-b 0.81 ± 0.06 0.83 ± 0.07 0.82 ± 0.08 0.93 ± 0.11
ab
 1.20 ± 0.10
a
 0.75 ± 0.06
b
 
SOCS3 1.33 ± 0.14 1.17 ± 0.06 1.42 ± 0.10 1.15 ± 0.16 1.05 ± 0.13 0.87 ± 0.11 
RAMP1 0.71 ± 0.07 0.74 ± 0.05 0.99 ± 0.10 1.14 ± 0.08 1.05 ± 0.07 1.20 ± 0.08 
RAMP2 1.22 ± 0.08 1.23 ± 0.06 1.23 ± 0.08 1.09 ± 0.04
 a
 1.04 ± 0.04
ab
 0.95 ± 0.03
b
 
RAMP3 0.87 ± 0.04 0.90 ± 0.07 1.04 ± 0.11 0.89 ± 0.10 1.08 ± 0.11 0.75 ± 0.09 
CTR1a 1.17 ± 0.10 1.23 ± 0.07 1.14 ± 0.07 0.72 ± 0.14
ab
 1.01 ± 0.15
a
 0.46 ± 0.10
b
 
CTR1b 1.06 ± 0.09 1.17 ± 0.07 0.97 ± 0.08 0.89 ± 0.15
ab
 1.27 ± 0.18
a
 0.46 ± 0.08
b
 
InsR 1.10 ± 0.07 1.03 ± 0.04 1.07 ± 0.05 0.94 ± 0.06 1.06 ± 0.05 0.91 ± 0.05 
NPY 0.84 ± 0.12
a
 1.33 ± 0.10
 b
 0.96 ± 0.07
a
    
AgRP 0.84 ± 0.10
a
 1.20 ± 0.07
 b
 0.80 ± 0.04
a
    
POMC 1.12 ± 0.11 1.10 ± 0.12 1.06 ± 0.10    
Values are mean ± SEM of duplicate determined mRNA levels as compared to relative mRNA levels of cyclophilin. N=9-10/group. Parameters 
with differing superscripts differ from each other by P<0.05 or less.  
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FIGURE LEGENDS 
Figure 1: 
125
I amylin binding in chow-fed rats. Dotted areas, hypothalamic ARC (arcuate), 
VMN (ventromedial nucleus), DMN (dorsomedial nucleus), Perifornical (PeF) and MTu (Medial 
Tuberal nucleus), MeA (Medial Amygdala) identified on the cresyl violet-stained slides used to 
generate the autoradiogram.   
 
Figure 2 (Experiment 1): Body weight gain (A) and food intake (B) in ad-libitum (Ad-Lib), 
amylin and pair-fed 9-10 wk old male rats after 5 d of systemic amylin (100µg/kg/d) vs. vehicle 
(0.9% saline) infusion with osmotic minipump. Vehicle was infused in Ad-Lib Fed and Pair-Fed 
groups. Values are mean ± SEM. N=9-10/group *P<0.05 or less. 
 
Figure 3 (Experiment 2): Body weight gain (A, C) and food intake (B, D) of LV infusions of 
IgG vs. IL-6 antibody for 5 d (A, B) followed by 5 d of systemic amylin (100µg/kg/d) vs. vehicle 
(0.9% saline) with osmotic minipump (C, D) in 9-10 wk old rats. Effect of LV infusions of IgG 
vs. IL-6 antibody and systemic amylin vs. saline on leptin-induced (5 mg/kg, ip) pSTAT3 
immunohistochemistry in the ARC and VMN (E). Images taken at 10X magnification (F, G, H). 
Values are mean ± SEM. N=8/group. Parameters with differing superscripts differ from each 
other by P<0.05 or less.  
 
Figure 4: Effect of systemic amylin or saline on leptin-induced (5 mg/kg, ip) pSTAT3 
immunohistochemistry in the ARC (A) and VMN (B) of saline- (wt-S) vs. amylin-treated (A; 
1mg/kg/day) wild type (wt-A) and saline- (IL-6 ko-S) vs. amylin-treated IL-6 knockout (IL-6 ko-
A) mice after 2 wk of systemic amylin (1mg/kg/d) vs. vehicle (0.9% saline) infusion with 
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osmotic minipump. Images taken at 20X magnification of wt-S (C) vs. IL-6 ko-S (E) and wt-A 
(D) vs. IL-6 ko-A (F). Values are mean ± SEM. N=8/group *P<0.05 or less wt-S vs. wt-A mice.    
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Supplementary figure 1 
Unlabelled amylin binding in chow-fed rats. Dotted areas, ARC (arcuate), VMN (ventromedial nucleus), DMN (dorsomedial 
nucleus), Perifornical (PeF), MTu (Medial Tuberal nucleus), MeA (Medial Amygdala) identified on the cresyl violet-stained slides 
used to generate the autoradiogram.   
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Supplementary figure 2 
Body weight gain (A) and Food intake (B) of saline- (wt-S) vs. amylin-treated (A; 1mg/kg/day) wild type (wt-A) and saline- (IL-6 ko-
S) vs. amylin-treated IL-6 knockout (IL-6 ko-A) mice after 2 wk of systemic amylin (1mg/kg/d) vs. vehicle (0.9% saline) infusion 
with osmotic minipump. Values are mean ± SEM. N=8/group *P<0.05 or less wt-S vs. wt-A mice. NB: all 4 groups are represented in 
B but overlap almost completely. 
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